30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Anika Therapeutics

Orthobiologic sales $16.5MM, +51%

  • U.S. ORTHOVISC +49%
  • Ex-U.S. S.r.l. orthobiologics flat (year-to-date +25%)
  • Year-to-date ex-U.S. viscosupplementation +39%


  • U.S. biologics sales represent 65% to 80% of overall biologic revenue
  • Commenced multinational Phase III 370-patient clinical study to support CE Mark for Cingal 3rd-generation single-injection osteoarthritis treatment
  • Expecting FDA’s definitive decision on MONOVISC pre-market approval by early 4Q
  • Not pursuing 510(k) filings for S.r.l. orthobiologics products
  • Since international launch in 2010, 2,000 patients treated to date with Hyalofast for regeneration of chondral and osteochondral defects in knee, ankle and shoulder